Terms: = Liver cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Treatment
88 results:
1. PELI1: key players in the oncogenic characteristics of pancreatic cancer.
Fei X; Zhu C; Liu P; Liu S; Ren L; Lu R; Hou J; Gao Y; Wang X; Pan Y
J Exp Clin Cancer Res; 2024 Mar; 43(1):91. PubMed ID: 38528516
[TBL] [Abstract] [Full Text] [Related]
2. Icaritin activates p53 and inhibits aerobic glycolysis in liver cancer cells.
Zhou X; Wu D; Mi T; Li R; Guo T; Li W
Chem Biol Interact; 2024 Apr; 392():110926. PubMed ID: 38431053
[TBL] [Abstract] [Full Text] [Related]
3. A Ubiquitin-Dependent Switch on MEF2D Senses Pro-Metastatic Niche Signals to Facilitate Intrahepatic Metastasis of liver cancer.
Xiang J; Zhang N; Du A; Li J; Luo M; Wang Y; Liu M; Yang L; Li X; Wang L; Liu Q; Chen D; Wang T; Bian XW; Qin ZY; Su L; Wen L; Wang B
Adv Sci (Weinh); 2023 Dec; 10(35):e2305550. PubMed ID: 37828611
[TBL] [Abstract] [Full Text] [Related]
4. Small-molecular cyclic peptide exerts viability suppression effects on HepG2 cells via triggering p53 apoptotic pathways.
Zhang H; Zhang H; Wang J; Fan L; Mu W; Jin Y; Wang Z
Chem Biol Interact; 2023 Sep; 382():110633. PubMed ID: 37451662
[TBL] [Abstract] [Full Text] [Related]
5. Clinical and Genomic Characteristics of Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors.
Rao X; Chen Y; Beyrer J; Nash Smyth E; Morato Guimaraes C; Litchfield LM; Bowman L; Lawrence GW; Aggarwal A; Andre F
Clin Cancer Res; 2023 Sep; 29(17):3372-3383. PubMed ID: 37289194
[TBL] [Abstract] [Full Text] [Related]
6. A Reduction of Calcineurin Inhibitors May Improve Survival in Patients with De Novo Colorectal cancer after liver Transplantation.
Ossami Saidy RR; Wegener E; Uluk D; Dittrich L; Schöning W; Lurje G; Öllinger R; Modest DP; Tacke F; Haase O; Pratschke J; Eurich D
Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556957
[TBL] [Abstract] [Full Text] [Related]
7. Nutlin-3 Promotes TRAIL-Induced liver cancer Cells Apoptosis by Activating p53 to Inhibit bcl-2 and Surviving Expression.
Zhang C; Ni J; Fan W; Hou J
Ann Clin Lab Sci; 2022 Jul; 52(4):601-610. PubMed ID: 36197780
[TBL] [Abstract] [Full Text] [Related]
8. miR-3,178 contributes to the therapeutic action of baicalein against hepatocellular carcinoma cells via modulating HDAC10.
Qi J; Li J; Bie B; Shi M; Zhu M; Tian J; Zhu K; Sun J; Mu Y; Li Z; Guo Y
Phytother Res; 2023 Jan; 37(1):295-309. PubMed ID: 36070933
[TBL] [Abstract] [Full Text] [Related]
9. p53 as a unique target of action of cisplatin in acute leukaemia cells.
Kumar S; Tchounwou PB
J Cell Mol Med; 2022 Sep; 26(17):4727-4739. PubMed ID: 35946055
[TBL] [Abstract] [Full Text] [Related]
10. Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy.
Dong X; Zhang Z; Zhang Q; Chen L; Cao G; Liu C; Song T; Lu W; Zhang W
J Cancer Res Clin Oncol; 2023 May; 149(5):1917-1927. PubMed ID: 35802197
[TBL] [Abstract] [Full Text] [Related]
11. Molecular imaging and treatment of PSMA-positive prostate cancer with
Jiao Y; Xu P; Luan S; Wang X; Gao Y; Zhao C; Fu P
Nucl Med Biol; 2022; 104-105():28-37. PubMed ID: 34847481
[TBL] [Abstract] [Full Text] [Related]
12. The Discovery of Potential mdm2 Inhibitors: A Combination of Pharmacophore Modeling, Virtual Screening, Molecular Docking Studies, and in vitro/in vivo Biological Evaluation.
Zhang X; Zhou C; Yang Y; Liu H; Wang S; Ding X; Wang H
ChemMedChem; 2022 Feb; 17(4):e202100517. PubMed ID: 34806333
[TBL] [Abstract] [Full Text] [Related]
13. Akt inhibitor augments anti-proliferative efficacy of a dual mTORC1/2 inhibitor by FOXO3a activation in p53 mutated hepatocarcinoma cells.
Patra T; Meyer K; Ray RB; Kanda T; Ray R
Cell Death Dis; 2021 Nov; 12(11):1073. PubMed ID: 34759291
[TBL] [Abstract] [Full Text] [Related]
14. A mechanistic insight into the biological activities of urolithins as gut microbial metabolites of ellagitannins.
Hasheminezhad SH; Boozari M; Iranshahi M; Yazarlu O; Sahebkar A; Hasanpour M; Iranshahy M
Phytother Res; 2022 Jan; 36(1):112-146. PubMed ID: 34542202
[TBL] [Abstract] [Full Text] [Related]
15. Genomic gain of
Cao P; Yang A; Li P; Xia X; Han Y; Zhou G; Wang R; Yang F; Li Y; Zhang Y; Cui Y; Ji H; Lu L; He F; Zhou G
Sci Adv; 2021 Aug; 7(35):. PubMed ID: 34433556
[TBL] [Abstract] [Full Text] [Related]
16. Inhibition of ribosomal RNA processing 15 Homolog (RRP15), which is overexpressed in hepatocellular carcinoma, suppresses tumour growth via induction of senescence and apoptosis.
Zhao D; Qian L; Zhuang D; Wang L; Cao Y; Zhou F; Zhang S; Liu Y; Liang Y; Zhang W; Kang W; Zhang M; Wang Y; Zhang F; Zhang W; Xiao J; Xu G; Lv Y; Zou X; Zhuge Y; Zhang B
Cancer Lett; 2021 Oct; 519():315-327. PubMed ID: 34343634
[TBL] [Abstract] [Full Text] [Related]
17. Larotrectinib in a Patient With Advanced Pleomorphic Liposarcoma of the Uterus.
Valenciaga A; Iwenofu OH; Tinoco G
J Natl Compr Canc Netw; 2021 Jul; 19(7):775-779. PubMed ID: 34340207
[TBL] [Abstract] [Full Text] [Related]
18. Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both mdm2 and SIRT1 signaling.
Yao JY; Xu S; Sun YN; Xu Y; Guo QL; Wei LB
Acta Pharmacol Sin; 2022 Apr; 43(4):1033-1045. PubMed ID: 34188177
[TBL] [Abstract] [Full Text] [Related]
19. Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer.
Wang K; Li L; Franch-Expósito S; Le X; Tang J; Li Q; Wu Q; Bassaganyas L; Camps J; Zhang X; Li H; Foukakis T; Xiang T; Wu J; Ren G
Mol Oncol; 2022 Jun; 16(12):2413-2431. PubMed ID: 34146382
[TBL] [Abstract] [Full Text] [Related]
20. miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy.
Chen E; Li E; Liu H; Zhou Y; Wen L; Wang J; Wang Y; Ye L; Liang T
Int J Biol Sci; 2021; 17(3):781-795. PubMed ID: 33767588
[TBL] [Abstract] [Full Text] [Related]
[Next]
